Recent research reveals that with each subsequent generation of Mexican Americans, the risk of developing liver cancer has climbed.
Researchers at the Mount Sinai Center for Transformative Disease Modeling have released a groundbreaking study identifying 4,749 key gene clusters, termed “prognostic modules,” that significantly influence the progression of 32 different types of cancer.
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center have developed an artificial intelligence model based on epigenetic factors that is able to predict patient outcomes successfully across multiple cancer types.
The American Society for Radiation Oncology has issued a clinical guideline on partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ.
The Association of Community Cancer Centers has released consensus-based Oncology Financial Advocacy Services Guidelines, a comprehensive framework developed to aid cancer programs and practices deliver services to patients that prevent, detect, and mitigate financial hardship during cancer care.
Oral nicotine pouches, a tobacco leaf-free product marketed as an alternative to cigarettes, do little to curb current smokers’ nicotine cravings, according to a study.
Preliminary data from Arm A1 of the phase II EDGE-Gastric study showed promising overall response rate and six-month progression-free-survival results, irrespective of PD-L1 expression.
Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.
A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.
UCLA scientists developed a novel method to engineer more powerful immune cells that can potentially be used for “off-the-shelf” cell therapy to treat challenging cancers.
